Michael Amdahl

1.8k total citations · 1 hit paper
14 papers, 1.3k citations indexed

About

Michael Amdahl is a scholar working on Nephrology, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Michael Amdahl has authored 14 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Nephrology, 10 papers in Pathology and Forensic Medicine and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Michael Amdahl's work include Parathyroid Disorders and Treatments (10 papers), Vitamin D Research Studies (10 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Michael Amdahl is often cited by papers focused on Parathyroid Disorders and Treatments (10 papers), Vitamin D Research Studies (10 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Michael Amdahl collaborates with scholars based in United States, Germany and United Kingdom. Michael Amdahl's co-authors include Stuart M. Sprague, Dick de Zeeuw, Eberhard Ritz, Daniel W. Coyne, Dennis L. Andress, Francisco Llach, Daniel Batlle, Paul Audhya, Giuseppe Remuzzi and Rajiv Agarwal and has published in prestigious journals such as The Lancet, Kidney International and American Journal of Kidney Diseases.

In The Last Decade

Michael Amdahl

14 papers receiving 1.3k citations

Hit Papers

Selective vitamin D receptor activation with paricalcitol... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    2010 520 citations Dick de Zeeuw, Rajiv Agarwal et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Amdahl United States 11 1.0k 675 277 234 211 14 1.3k
Michael Freundlich United States 19 511 0.5× 310 0.5× 238 0.9× 212 0.9× 130 0.6× 45 1.1k
João Frazão Portugal 18 898 0.9× 377 0.6× 177 0.6× 250 1.1× 127 0.6× 66 1.1k
Christie Lorriaux France 14 873 0.9× 306 0.5× 108 0.4× 235 1.0× 218 1.0× 34 1000
Brice Mayor France 14 820 0.8× 306 0.5× 105 0.4× 230 1.0× 192 0.9× 30 953
Shigeichi Shoji Japan 16 469 0.5× 236 0.3× 83 0.3× 121 0.5× 93 0.4× 59 982
M. Emoto Japan 16 477 0.5× 226 0.3× 94 0.3× 100 0.4× 160 0.8× 19 1.2k
Howard J. Heller United States 17 459 0.5× 184 0.3× 223 0.8× 176 0.8× 164 0.8× 24 1.1k
Richard Nissel Germany 14 363 0.4× 98 0.1× 303 1.1× 72 0.3× 125 0.6× 18 788
Young Shin Shin South Korea 10 297 0.3× 265 0.4× 71 0.3× 108 0.5× 106 0.5× 18 628
Joana E. Kist‐van Holthe Netherlands 22 336 0.3× 148 0.2× 344 1.2× 90 0.4× 154 0.7× 44 1.1k

Countries citing papers authored by Michael Amdahl

Since Specialization
Citations

This map shows the geographic impact of Michael Amdahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Amdahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Amdahl more than expected).

Fields of papers citing papers by Michael Amdahl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Amdahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Amdahl. The network helps show where Michael Amdahl may publish in the future.

Co-authorship network of co-authors of Michael Amdahl

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Amdahl. A scholar is included among the top collaborators of Michael Amdahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Amdahl. Michael Amdahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Bernardo, Angelito A., Thomas Marbury, Phil McFarlane, et al.. (2016). Clinical safety and performance of VIVIA: a novel home hemodialysis system. Nephrology Dialysis Transplantation. 32(4). 685–692. 7 indexed citations
2.
Kirsch, Alexander H., Lars‐Göran Nilsson, Werner Beck, et al.. (2016). Performance of hemodialysis with novel medium cut-off dialyzers. Nephrology Dialysis Transplantation. 32(1). 165–172. 172 indexed citations
3.
Kirsch, Alexander H., Lars‐Göran Nilsson, Werner Beck, et al.. (2016). SP416LARGE MIDDLE-MOLECULE REMOVAL DURING HEMODIALYSIS USING A NOVEL MEDIUM CUTOFF DIALYZER. Nephrology Dialysis Transplantation. 31(suppl_1). i230–i230. 1 indexed citations
4.
Coyne, Daniel W., D.L. Andress, Michael Amdahl, Eberhard Ritz, & Dick de Zeeuw. (2013). Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrology Dialysis Transplantation. 28(9). 2260–2268. 32 indexed citations
5.
Yan, Yucheng, Jiaqi Qian, Nan Chen, et al.. (2013). Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects. Clinical Nephrology. 81(1). 20–29. 4 indexed citations
6.
Ketteler, Markus, Kévin Martin, Myles Wolf, et al.. (2012). Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology Dialysis Transplantation. 27(8). 3270–3278. 79 indexed citations
7.
Ketteler, M., Kévin Martin, Mario Cozzolino, et al.. (2011). Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation. 27(5). 1942–1949. 25 indexed citations
8.
Zeeuw, Dick de, Rajiv Agarwal, Michael Amdahl, et al.. (2010). Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet. 376(9752). 1543–1551. 520 indexed citations breakdown →
9.
Heerspink, Hiddo J.L., Rajiv Agarwal, Daniel W. Coyne, et al.. (2009). The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. American Journal of Nephrology. 30(3). 280–286. 28 indexed citations
10.
Lund, Richard, Dennis L. Andress, Michael Amdahl, Laura Williams, & Robert P. Heaney. (2009). Differential Effects of Paricalcitol and Calcitriol on Intestinal Calcium Absorption in Hemodialysis Patients. American Journal of Nephrology. 31(2). 165–170. 37 indexed citations
11.
Greenbaum, Larry A., Nadine Benador, Stuart L. Goldstein, et al.. (2007). Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis. American Journal of Kidney Diseases. 49(6). 814–823. 33 indexed citations
12.
Amdahl, Michael, et al.. (2004). Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrology Dialysis Transplantation. 19(5). 1174–1181. 85 indexed citations
13.
Sprague, Stuart M., et al.. (2003). Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International. 63(4). 1483–1490. 270 indexed citations
14.
Martin, Kévin, et al.. (2001). Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blind, multicenter, randomized study. American Journal of Kidney Diseases. 38(5). S57–S63. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Freundlich Breakdown of academic impact, for papers by João Frazão Breakdown of academic impact, for papers by Christie Lorriaux Breakdown of academic impact, for papers by Brice Mayor Breakdown of academic impact, for papers by Shigeichi Shoji Breakdown of academic impact, for papers by M. Emoto Breakdown of academic impact, for papers by Howard J. Heller Breakdown of academic impact, for papers by Richard Nissel Breakdown of academic impact, for papers by Young Shin Shin Breakdown of academic impact, for papers by Joana E. Kist‐van Holthe
Rankless by CCL
2026